VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines

(RTTNews) - Anixa Biosciences, Inc. (ANIX) has entered into a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions, headquartered in Vienna, Austria, is pioneering personalized cancer treatment by integrating artificial intelligence and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines.

VERDI has granted Anixa a six-month exclusive right to negotiate a transaction for the research, development, and commercialization of VERDI's cancer vaccines. While VERDI continues to develop personalized vaccines for individual treatment attempts in Europe, VERDI and Anixa plan to initiate clinical trials in the U.S.

Shares of Anixa Biosciences are up 5% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.